Author: Pervushin, Konstantin; Tan, Edward; Parthasarathy, Krupakar; Lin, Xin; Jiang, Feng Li; Yu, Dejie; Vararattanavech, Ardcharaporn; Soong, Tuck Wah; Liu, Ding Xiang; Torres, Jaume
Title: Structure and Inhibition of the SARS Coronavirus Envelope Protein Ion Channel Document date: 2009_7_10
ID: 1e102wrc_4
Snippet: There is therefore an urgent need to know more about the coronavirus life cycle, and about new ways to battle infection. Protective efficacy of candidate vaccines against coronaviruses in humans has been mainly studied in animals so far, and only few vaccines have entered Phase 1 human trials [11] . Other compounds [12] [13] [14] [15] [16] [17] have shown activity against SARS-CoV and HCoV-229E, but there is no data from animal studies or clinica.....
Document: There is therefore an urgent need to know more about the coronavirus life cycle, and about new ways to battle infection. Protective efficacy of candidate vaccines against coronaviruses in humans has been mainly studied in animals so far, and only few vaccines have entered Phase 1 human trials [11] . Other compounds [12] [13] [14] [15] [16] [17] have shown activity against SARS-CoV and HCoV-229E, but there is no data from animal studies or clinical trials [18] . Studies of antiviral therapy against coronaviruses other than SARS-CoV have been scarce; in vitro data show that several chemicals may have inhibitory activities on HCoV-NL63 and HCoV-229E [19, 20] , but there have not been clinical trials on therapy of infections caused by human coronaviruses HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-HKU1.
Search related documents:
Co phrase search for related documents- animal study and candidate vaccine: 1, 2, 3, 4
- animal study and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9
- animal study and clinical trial animal study: 1
- animal study and inhibitory activity: 1
- animal study and life cycle: 1, 2
- animal study and protective efficacy: 1, 2
- animal study and SARS CoV activity: 1, 2
- animal study and urgent need: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral therapy and candidate vaccine: 1, 2, 3, 4, 5
- antiviral therapy and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41
- antiviral therapy and coronavirus life cycle: 1
- antiviral therapy and inhibitory activity: 1, 2, 3, 4
- antiviral therapy and life cycle: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- antiviral therapy and SARS CoV activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- antiviral therapy and SARS CoV activity show: 1, 2
- antiviral therapy and urgent need: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
- battle infection and clinical trial: 1, 2
- battle infection and urgent need: 1, 2
- candidate vaccine and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44
Co phrase search for related documents, hyperlinks ordered by date